非小细胞肺癌和表皮生长因子受体突变患者的脑转移 - Suppr

Suppr

超能文献

Brain metastasis in patients with non-small-cell lung cancer and epidermal growth factor receptor mutations.

作者信息

Bhatt Vijaya R, Kedia Shiksha, Kessinger Anne, Ganti Apar K

出版信息

J Clin Oncol. 2013 Sep 1;31(25):3162-4. doi: 10.1200/JCO.2013.49.8915. Epub 2013 Jul 29.

DOI:10.1200/JCO.2013.49.8915

PMID:23897953

Abstract

摘要

相似文献

Brain metastasis in patients with non-small-cell lung cancer and epidermal growth factor receptor mutations.非小细胞肺癌和表皮生长因子受体突变患者的脑转移

J Clin Oncol. 2013 Sep 1;31(25):3162-4. doi: 10.1200/JCO.2013.49.8915. Epub 2013 Jul 29.

Should erlotinib be coadministered with whole-brain radiotherapy in patients with brain metastases and non-small-cell lung cancer?在患有脑转移瘤的非小细胞肺癌患者中，厄洛替尼是否应与全脑放疗联合使用？

J Clin Oncol. 2013 Sep 1;31(25):3164-5. doi: 10.1200/JCO.2013.50.0710. Epub 2013 Jul 29.

Reply to v.R. Bhatt et Al and m.C. Chamberlain.对v.R. 巴特等人及m.C. 张伯伦的回复。

J Clin Oncol. 2013 Sep 1;31(25):3165-6. doi: 10.1200/JCO.2013.50.7160. Epub 2013 Jul 29.

Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.厄洛替尼对比全脑放疗用于表皮生长因子受体突变型非小细胞肺癌伴多发脑转移患者（BRAIN）：一项多中心、三期、开放标签、平行、随机对照临床试验。

Lancet Respir Med. 2017 Sep;5(9):707-716. doi: 10.1016/S2213-2600(17)30262-X. Epub 2017 Jul 19.

CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.厄洛替尼治疗对一名伴有EGFR突变的转移性非小细胞肺癌患者的中枢神经系统反应。

Nat Clin Pract Oncol. 2007 Oct;4(10):603-7. doi: 10.1038/ncponc0931.

Increasing osteoblastic lesions as a manifestation of a major response to gefitinib.

J Thorac Oncol. 2006 Oct;1(8):859-60.

Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.EGFR 突变阳性的晚期非小细胞肺癌患者一线使用吉非替尼治疗的总生存预后因素的真实世界数据。

Oncologist. 2017 Sep;22(9):1075-1083. doi: 10.1634/theoncologist.2016-0331. Epub 2017 May 15.

Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutations.颅内转移瘤对表皮生长因子受体酪氨酸激酶抑制剂的反应：这可能完全取决于表皮生长因子受体（EGFR）突变。

J Clin Oncol. 2008 Feb 1;26(4):686. doi: 10.1200/JCO.2007.15.1944.

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.表皮生长因子受体酪氨酸激酶抑制剂对携带外显子 19 或 21 突变的非小细胞肺癌脑转移患者的疗效。

Lung Cancer. 2012 Sep;77(3):556-60. doi: 10.1016/j.lungcan.2012.05.092. Epub 2012 Jun 5.

[Lung cancer: an update in 2010].[肺癌：2010年最新进展]

Bull Cancer. 2010 Jan;97(1):161-9. doi: 10.1684/bdc.2010.1026.

引用本文的文献

Survival outcomes of upfront versus delayed craniocerebral radiotherapy in EGFR-mutant NSCLC patients treated with third-generation EGFR-TKIs.接受第三代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）治疗的表皮生长因子受体（EGFR）突变型非小细胞肺癌（NSCLC）患者中， upfront与延迟颅脑放疗的生存结局

Clin Exp Metastasis. 2025 Sep 6;42(5):51. doi: 10.1007/s10585-025-10369-8.

The cancer stem cells characteristics analysis of LGR5 + cells that influence lung cancer risk by using single cell RNA-seq analysis.利用单细胞RNA测序分析影响肺癌风险的LGR5+细胞的癌症干细胞特征

Sci Rep. 2025 May 8;15(1):16085. doi: 10.1038/s41598-025-00585-3.

Diagnostic accuracy of MRI-based radiomic features for EGFR mutation status in non-small cell lung cancer patients with brain metastases: a meta-analysis.基于MRI的影像组学特征对非小细胞肺癌脑转移患者EGFR突变状态的诊断准确性：一项荟萃分析

Front Oncol. 2025 Jan 6;14:1428929. doi: 10.3389/fonc.2024.1428929. eCollection 2024.

Optimal intervention timing for craniocerebral radiotherapy in EGFR mutant lung adenocarcinoma patients with brain metastases.表皮生长因子受体（EGFR）突变型肺腺癌脑转移患者颅脑放疗的最佳干预时机

BMC Cancer. 2024 Dec 23;24(1):1571. doi: 10.1186/s12885-024-13363-7.

Treatment outcomes of EGFR-TKI with or without locoregional brain therapy in advanced EGFR-mutant non-small cell lung cancer patients with brain metastases.表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）联合或不联合局部脑部治疗用于晚期EGFR突变型非小细胞肺癌脑转移患者的治疗结局

Contemp Oncol (Pozn). 2023;27(2):71-79. doi: 10.5114/wo.2023.129366. Epub 2023 Jul 11.

LncRNA CYP4A22-AS1 promotes the progression of lung adenocarcinoma through the miR-205-5p/EREG and miR-34c-5p/BCL-2 axes.长链非编码RNA CYP4A22-AS1通过miR-205-5p/表皮调节素和miR-34c-5p/凋亡抑制蛋白2轴促进肺腺癌进展。

Cancer Cell Int. 2023 Sep 5;23(1):194. doi: 10.1186/s12935-023-03036-z.

A visualized dynamic prediction model for overall survival in patients diagnosed with brain metastases from lung squamous cell carcinoma.一个用于诊断为肺鳞癌脑转移患者的总生存的可视化动态预测模型。

Clin Respir J. 2023 Jun;17(6):556-567. doi: 10.1111/crj.13625. Epub 2023 Apr 29.

The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis.安罗替尼治疗高级别胶质瘤的疗效及不良反应：一项回顾性分析。

Front Oncol. 2023 Feb 17;13:1095362. doi: 10.3389/fonc.2023.1095362. eCollection 2023.

Effect of EGFR-TKIs combined with craniocerebral radiotherapy on the prognosis of -mutant lung adenocarcinoma patients with brain metastasis: A propensity-score matched analysis.表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）联合颅脑放疗对伴有脑转移的EGFR突变型肺腺癌患者预后的影响：一项倾向评分匹配分析

Front Oncol. 2023 Feb 9;13:1049855. doi: 10.3389/fonc.2023.1049855. eCollection 2023.

The dynamic dysregulated network identifies stage-specific markers during lung adenocarcinoma malignant progression and metastasis.动态失调网络可识别肺腺癌恶性进展和转移过程中的阶段特异性标志物。

Mol Ther Nucleic Acids. 2022 Nov 22;30:633-647. doi: 10.1016/j.omtn.2022.11.019. eCollection 2022 Dec 13.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验